Factors Contributing to Initial Weight Loss Among Adolescents with Polycystic Ovary Syndrome

Journal of Pediatric and Adolescent Gynecology

Volumn 25, Issue 6, 2012, Pages 367-370

  Geier, L M ^a   Bekx, M T ^a   Connor, E L ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Dietitian; Polycystic ovary syndrome; Psychologist; Weight loss

Indexed keywords

METFORMIN;

ADOLESCENT; ADULT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; DIETITIAN; ENDOCRINOLOGIST; FEMALE; FOLLOW UP; GYNECOLOGIST; HUMAN; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PSYCHOLOGIST; RETROSPECTIVE STUDY; WEIGHT CHANGE; WEIGHT CONTROL; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; BEHAVIOR THERAPY; BODY MASS INDEX; CHILD; DIETETICS; ENDOCRINOLOGY; FEMALE; FOOD HABITS; GYNECOLOGY; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OBESITY; PATIENT CARE TEAM; PATIENT COMPLIANCE; POLYCYSTIC OVARY SYNDROME; PSYCHOLOGY; RETROSPECTIVE STUDIES; WEIGHT LOSS; YOUNG ADULT;

EID: 84869146657     PISSN: 10833188     EISSN: 18734332     Source Type: Journal    
DOI: 10.1016/j.jpag.2012.06.008     Document Type: Article

References (23)

1. Futterweit W. Polycystic ovary syndrome: a common reproductive and metabolic disorder necessitating early recognition and treatment. Prim Care 2007, 34:761.
2. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004, 19:41. Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group.
3. Mukherjee S., Maitra A. Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome. Indian J Med Res 2010, 131:743.
4. Ehrmann D.A., Barnes R.B., Rosenfield R.L., et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovarian syndrome. Diabetes Care 1999, 22:141.
5. Legro R.S., Kunselman A.R., Dodson W.C., et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999, 84:165.
6. Nestler J.E. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008, 358:47.
7. Essah P.A., Wickham E.P., Nestler J.E. The metabolic syndrome in polycystic ovary syndrome. Clin Obstet Gynecol 2007, 50:205.
8. Apridonidze T., Essah P.A., Iuorno M.G., et al. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90:1929.
9. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356.
10. Wild R.A., Carmina E., Diamanti-Kandarakis E., et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010, 95:2038.
11. Bekx M.T., Connor E.L., Allen D.B. Characteristics of adolescents presenting to a multidisciplinary clinic for polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2010, 23:7.
12. Norman R.J., Davies M.J., Lord J., et al. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002, 13:251.
13. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003, 24:1601. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.
14. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393. Diabetes Prevention Program Research Group.
15. Sharma S.T., Wickman E.P., Nestler J.E. Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis. Endocr Pract 2007, 13:373.
16. Andersen P., Seljeflot I., Abdelnoor M., et al. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995, 44:611.
17. Benson S., Hahn S., Tan S., et al. Prevalence and implications of anxiety in polycystic ovary syndrome: results of an internet-based survey in Germany. Hum Reprod 2009, 24:1446.
18. Farrell K., Antoni M.H. Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions. Fertil Steril 2010, 94:1565.
19. Rassi A., Veras A.B., dos Reis M., et al. Prevalence of psychiatric disorders in patients with polycystic ovary syndrome. Compr Psychiatry 2010, 51:599.
20. Abramson M., Torghele J.R. Weight, temperature changes, and psychosomatic symptomatology in relation to the menstrual cycle. Am J Obstet Gynecol 1961, 81:223.
21. Thorn F., Nelson K., Thorn D. A study of the mechanism of edema associated with menstruation. Endocrinology 1938, 22:155.
22. Bruce J., Russell G.F. Premenstrual tension: a study of weight changes and balances of water, sodium, and potassium. Lancet 1962, 2(7250):267.
23. Janowsky D.S., Berens S.C., Davis J.M. Correlations between mood, weight, and electrolytes during the menstrual cycle: a renin-angiotensin-aldosterone hypothesis of premenstrual tension. Psy Med 1973, 35:143.